Allogeneic Alternatives to Autologous Bone Marrow: The MSC Combined Cell Strategies

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The successful application of autologous and allogeneic stem cell therapy for heart disease has prompted more recent preclinical, and a few clinical, studies examining the safety and efficacy of combining two different types of stem cells. In virtually all instances, the combination worked better at reducing scar size and/or improving cardiac function than either cell type alone providing impetus for using two cell types together as a novel therapeutic strategy. This success is moving the field closer to combination therapy clinical trials, the first of which will examine a mix of mesenchymal and cardiac stem cells.

Original languageEnglish (US)
Title of host publicationStem Cell and Gene Therapy for Cardiovascular Disease
PublisherElsevier Science Ltd.
Pages181-192
Number of pages12
ISBN (Electronic)9780128018637
ISBN (Print)9780128018880
DOIs
StatePublished - Jan 1 2015

Keywords

  • Allogeneic
  • Cardiac stem cells
  • Combination therapy
  • Mesenchymal stem cells
  • Myocardial infarction

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Allogeneic Alternatives to Autologous Bone Marrow: The MSC Combined Cell Strategies'. Together they form a unique fingerprint.

  • Cite this